9 Specific Body Composition Measurements Beyond BMI That Menopausal Women Should Be Tracking
The number on the scale didn't change much for me — and for a long time that felt reassuring. It wasn't until someone looked past BMI that the real picture emerged: fat quietly migrating inward, muscle quietly disappearing, and a waistband that kept needing to be let out despite 'normal' weight. If that story sounds familiar, these measurements are the ones worth paying attention to.
Learn more about Rose →Waist Circumference
Visceral fat — the metabolically active fat packed around abdominal organs — increases substantially after menopause even when total body weight stays stable, and waist circumference is the simplest proxy for it. A measurement above 88 cm (35 inches) in women is associated with significantly elevated risk of cardiovascular disease, insulin resistance, and type 2 diabetes. It takes 30 seconds with a tape measure and tells a story BMI never could.
Waist-to-Hip Ratio (WHR)
Where fat is stored matters as much as how much fat is stored, and waist-to-hip ratio captures the shift from gynoid (hip-and-thigh) to android (abdominal) fat distribution that estrogen decline triggers. A WHR above 0.85 in women is classified by the WHO as high risk for metabolic and cardiovascular complications. Research consistently shows WHR outperforms BMI in predicting all-cause mortality in postmenopausal women specifically.
Waist-to-Height Ratio (WHtR)
Waist-to-height ratio — simply waist circumference divided by height — adjusts for body size in a way that pure waist circumference cannot, making it more comparable across different statures. A value above 0.5 is the widely cited threshold for elevated cardiometabolic risk, and some research suggests it predicts cardiovascular events more accurately than either BMI or waist circumference alone. For menopausal women, it is an inexpensive, immediate screening number worth knowing.
Appendicular Lean Mass Index (ALMI)
Appendicular lean mass — the combined skeletal muscle of the arms and legs — is the single most clinically meaningful marker of sarcopenia risk, and menopause accelerates its loss through estrogen-related decline in muscle protein synthesis. ALMI is calculated from a DEXA scan as appendicular lean mass in kilograms divided by height in meters squared, with low values in women defined as below 5.5 kg/m². Identifying low ALMI early is what makes resistance training and protein optimization interventions genuinely time-sensitive rather than optional.
Visceral Adipose Tissue Volume (VAT)
Unlike subcutaneous fat sitting just beneath the skin, visceral adipose tissue secretes inflammatory cytokines and free fatty acids directly into the portal circulation, driving insulin resistance and dyslipidemia. VAT volume can be measured precisely by MRI or estimated by DEXA scan with body composition software, and it increases disproportionately during the menopausal transition even in women whose total fat mass changes little. Elevated VAT is a stronger predictor of metabolic syndrome than total body fat percentage in postmenopausal women.
Body Fat Percentage
Two women can share an identical BMI while one carries 38% body fat and the other carries 24% — a distinction with profound health implications that BMI erases entirely. Body fat percentage can be measured via DEXA scan (gold standard), air displacement plethysmography (BodPod), or estimated through bioelectrical impedance, with healthy ranges for postmenopausal women generally cited between 24–36% depending on the reference population used. Because lean mass declines at menopause while fat mass often rises, body fat percentage frequently climbs even when weight appears static on the scale.
Bone Mineral Density (BMD) T-Score
Estrogen actively suppresses osteoclast activity — the cells that break down bone — so its decline at menopause triggers accelerated bone loss that can reach 1–3% per year in the years immediately following the final period. DEXA-derived T-scores compare a woman's bone density to a young adult reference peak, with scores between -1.0 and -2.5 indicating osteopenia and below -2.5 indicating osteoporosis. Catching low BMD before a fracture occurs is the entire point, and guidelines recommend baseline DEXA screening at menopause for women with risk factors and universally at age 65.
Fat Mass Index (FMI)
Fat mass index isolates the fat component of body composition by expressing fat mass in kilograms relative to height squared, analogous to how BMI is calculated but using only fat mass rather than total weight. This distinction matters because BMI conflates fat and muscle — a woman who gains fat while losing muscle can maintain an identical BMI while her cardiometabolic risk profile worsens significantly. FMI derived from DEXA provides a cleaner, height-adjusted measure of adiposity that tracks more meaningfully with inflammatory and insulin-resistance markers in menopausal women.
Grip Strength
Handgrip strength measured with a calibrated dynamometer is a validated, low-tech surrogate for whole-body skeletal muscle function and a surprisingly powerful predictor of long-term health outcomes including cardiovascular mortality, disability, and fall risk. In postmenopausal women, low grip strength — generally defined as below 20 kg in research settings, though thresholds vary — is one of the three diagnostic criteria for sarcopenia alongside low muscle mass and poor physical performance. It takes two minutes in any clinical setting and tracks muscle functional quality rather than just quantity, making it a practical complement to DEXA-based lean mass measurements.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.